Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24252

Title:	Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.
Authors:	Bearz, A;Martini, JF;Jassem, J;Kim, SW;Chang, GC;Shaw, A;Shepard, D;Dall'O', E;Polli, A;Thurm, H;Zalcman, G;Campelo, MRG;Penkov, K;Hayashi, H;Solomon, BJ
Date:	2021
Issue Date:	2022-08-05T10:45:33Z (UTC)
Publisher:	AMER ASSOC CANCER RESEARCH
ISSN:	0008-5472
URI:	https://www.webofscience.com/wos/woscc/full-record/WOS:000680263501122 https://ir.csmu.edu.tw:8080/handle/310902500/24252
Relation:	CANCER RESEARCH ,2021 ,v81 ,issue13
Appears in Collections:	[中山醫學大學研究成果] 其他文獻

Files in This Item:

There are no files associated with this item.